Novel molecular point-of-care assay yielded results within 30 minutes with acceptable sensitivity and specificity.
Rapid diagnostics for gonorrhea and chlamydia would diminish the required effort of contacting patients for follow-up and administration of medication, thereby also avoiding unnecessary therapies for those treated empirically at the clinic visit. To evaluate the performance of a novel point-of-care (POC) 30-minute molecular test that uses vaginal swabs from women and urine samples from men, investigators conducted a manufacturer-sponsored study involving 1523 women and 922 men seen at 11 U.S. clinics.
According to gold-standard assays used for comparison, prevalence of gonorrhea was 3% among women and 8% among men, and of chlamydia was 8% (women) and 13% (men). Sensitivity of the POC test in women was 100% for gonorrhea and 96% for chlamydia…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)